SLK, an Altimetrik Company named Major Contender in Everest Group’s Application Transformation Services for AI-enablement PEAK Matrix Assessment 2025
BANGALORE, India, Dec. 24, 2025 /PRNewswire/ -- SLK, an Altimetrik Company has…
HKUST and SEMI Co-Host Inaugural 2025 Semiconductor Innovation and Intelligent Application Summit (SIIAS)
Uniting Global Semiconductor Leaders to Drive Industry Innovation and GrowthHONG KONG, Dec.…
Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy
Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase…
Alvotech Provides Update on the Status ofU.S. Biologics License Application for AVT05
REYKJAVIK, Iceland, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a…
Junshi Biosciences Announces FDAs Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients
SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd…
Bybit Kazakhstan Launches Pilot for QR-Based Digital Asset Payments as NBK Sandbox Application Progresses
DUBAI, UAE, Sept. 29, 2025 /PRNewswire/ -- Bybit Limited (Bybit Kazakhstan), a…
Oliva launches GeneIQ – India’s First DNA-Based Derma Clinic Application
Over 130 genes and 150 traits analysed to provide personalised skin careGeneIQ…
Opterion Health AG submits Clinical Trial Application for First-in-Human Study of OPT101 in Patients with Advanced Chronic Kidney Disease
MUTTENZ, Switzerland, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Opterion Health AG, a…
Imaging Endpoints Announces Patent Application for AI Review Charter System
SCOTTSDALE, Ariz., Sept. 10, 2025 /PRNewswire/ -- Imaging Endpoints (IE), the global…
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI IQLIK(lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimers Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and…
